Autolus Therapeutics (NASDAQ:AUTL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a sell rating to a hold rating in a report released on Sunday morning.

Several other brokerages also recently issued reports on AUTL. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Weiss Ratings downgraded Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Finally, Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $2.29 on Friday. The company’s 50-day moving average is $1.67 and its 200-day moving average is $1.58. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The firm has a market capitalization of $609.51 million, a PE ratio of -2.16 and a beta of 2.07. Autolus Therapeutics has a fifty-two week low of $1.17 and a fifty-two week high of $2.43.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The business had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million. Equities analysts forecast that Autolus Therapeutics will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Alphabet Inc. acquired a new stake in shares of Autolus Therapeutics in the second quarter valued at approximately $1,117,000. Syncona Portfolio Ltd acquired a new stake in Autolus Therapeutics during the second quarter worth approximately $26,625,152,000. Hennion & Walsh Asset Management Inc. grew its position in Autolus Therapeutics by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after buying an additional 11,197 shares in the last quarter. GAMMA Investing LLC increased its stake in Autolus Therapeutics by 115.6% during the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after acquiring an additional 8,309 shares during the period. Finally, Waverly Advisors LLC bought a new position in Autolus Therapeutics during the 1st quarter worth $37,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.